The liver endures a remarkable spectrum of insults, from intrinsic dose-dependent toxins like acetaminophen to idiosyncratic drug reactions that defy prediction, with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) now representing the most common chronic liver condition globally and alcohol remaining a leading cause of cirrhosis-related mortality [1] [2] [3]. Understanding how medications, metabolic factors, viral infections, genetic disorders, and alcohol each injure hepatic tissue enables clinicians to identify reversible causes early and prevent progression to fibrosis, cirrhosis, and hepatocellular carcinoma. During your physical at Castle Rock Primary Care, we will evaluate for any liver inflammation with routine blood work. Schedule Now

Medication-induced hepatotoxicity

Drug-induced liver injury (DILI) spans two fundamental mechanisms. Intrinsic DILI is dose-dependent and predictable—acetaminophen overdose exemplifies this, generating toxic metabolites that deplete glutathione and cause centrilobular necrosis [4]. Idiosyncratic DILI is far more challenging: it occurs rarely (1 in 5,000 to 100,000 exposures), lacks clear dose-dependency, and emerges after weeks to months of therapy [5]. The 2021 ACG guideline emphasizes that DILI remains a diagnosis of exclusion, requiring careful attribution via tools like the Roussel Uclaf Causality Assessment Method (RUCAM) [6].

High-risk agents include amoxicillin-clavulanate (most common antimicrobial cause), anti-tuberculosis medications (isoniazid, rifampin), NSAIDs, statins, and increasingly herbal and dietary supplements [7] [8]. Immune checkpoint inhibitors have emerged as a distinct cause with autoimmune features [9]. The 2023 AASLD guidance recommends systematic evaluation including latency analysis, exclusion of competing etiologies, and awareness that DILI can mimic virtually all known hepatopathies [10].

Metabolic dysfunction-associated steatotic liver disease

MASLD affects approximately 30% of adults in Western populations, with 20–30% progressing to steatohepatitis (MASH) that can advance to cirrhosis and hepatocellular carcinoma [2] [11]. The pathophysiology involves insulin resistance, lipotoxicity, mitochondrial dysfunction, and inflammatory cascades. Liver fibrosis represents the strongest predictor of disease progression and mortality [12].

Management remains anchored in weight loss (≥7–10% for histologic improvement), with pioglitazone used off-label for fibrosis reduction in diabetic patients and vitamin E considered in non-diabetic adults [12]. The 2021 Gastroenterology consensus highlighted cardiovascular risk as the predominant cause of death in MASLD, underscoring the need for integrated metabolic management [2].

Viral hepatitis

Chronic hepatitis B and C infection drive cirrhosis and hepatocellular carcinoma worldwide. HBV causes immune-mediated hepatocyte injury with risk of reactivation during immunosuppression; HCV leads to progressive fibrosis through direct cytopathic and immune mechanisms. Notably, alcohol synergizes with viral hepatitis to accelerate fibrosis progression and HCC development—an interaction that demands particular vigilance in patients with dual exposure [13].

Genetic and inherited disorders

Hereditary hemochromatosis (HFE mutations) causes iron overload with cirrhosis risk; Wilson disease (ATP7B mutations) produces copper accumulation and can present with acute liver failure in young adults; alpha-1 antitrypsin deficiency leads to polymerization of misfolded protein in hepatocytes [14]. These conditions often present with cryptogenic liver enzyme elevations or family history, and their identification enables targeted therapy (phlebotomy for hemochromatosis, chelation for Wilson disease) and cascade screening of relatives.

Alcohol-related liver disease

Alcohol-related liver disease (ALD) accounts for nearly 90% of alcohol-related deaths in some regions, with risk increasing exponentially above consumption thresholds—though individual susceptibility varies dramatically [3]. The spectrum progresses from steatosis (reversible with abstinence) to steatohepatitis and cirrhosis, with alcoholic hepatitis representing a high-mortality acute presentation [15]. The 2020 AASLD guidance emphasizes that abstinence remains the cornerstone of management at all stages, with liver transplantation appropriate for selected patients with decompensated disease [16].

Clinical approach to suspected liver injury

When evaluating elevated liver enzymes, consider the pattern of injury: hepatocellular (ALT-predominant) versus cholestatic (ALP-predominant) versus mixed. The AST:ALT ratio offers diagnostic clues—values >2 suggest alcohol-related disease, while isolated ALP elevation raises concern for biliary obstruction or cholestatic DILI [17]. The 2022 EASL guideline recommends structured causality assessment and early referral to transplant centers when DILI progresses to acute liver failure [18].

Sources:

  1. Drug-induced liver injury-types and phenotypes. The New England Journal of Medicine, 2019
  2. Preparing for the NASH epidemic: a call to action. Gastroenterology, 2021
  3. Alcohol use disorder and the liver. Addiction, 2021
  4. Drug-induced liver injury: advances in mechanistic understanding that will inform risk management. Clinical Pharmacology and Therapeutics, 2017
  5. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology, 2010
  6. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. The American Journal of Gastroenterology, 2021
  7. Adverse drug reactions and organ damage: the liver. European Journal of Internal Medicine, 2016
  8. Drug-induced liver injury in GI practice. Hepatology Communications, 2020
  9. Drug-induced liver injury. Nature Reviews: Disease Primers, 2019
  10. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology, 2023
  11. Preparing for the NASH epidemic: a call to action. Diabetes Care, 2021
  12. Management of non-alcoholic fatty liver disease. BMJ, 2021
  13. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology, 2011
  14. Liver cirrhosis. Lancet, 2008
  15. Recent advances in alcoholic hepatitis. F1000research, 2020
  16. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2020
  17. Drug-induced cholestatic liver diseases. Hepatology, 2025
  18. EASL clinical practice guidelines: drug-induced liver injury. Journal of Hepatology, 2019